| scholarly article | Q13442814 |
| P50 | author | Claudia Ciano | Q58361018 |
| Giovanni Ferrara | Q59712510 | ||
| Carlo Antozzi | Q66725195 | ||
| Renato Mantegazza | Q43161279 | ||
| Pietro Ghezzi | Q46434981 | ||
| Giuseppe Lauria | Q47739372 | ||
| Lorenzo Maggi | Q55090017 | ||
| P2093 | author name string | Graziella Filippini | |
| Angela Campanella | |||
| Paola Penza | |||
| Dario Caldiroli | |||
| Filippo Ghelma | |||
| Alfredo Martini | |||
| Pinuccia Beretta | |||
| P2860 | cites work | A novel endogenous erythropoietin mediated pathway prevents axonal degeneration | Q28579124 |
| Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades | Q34086191 | ||
| Nonhematopoietic erythropoietin derivatives prevent motoneuron degeneration in vitro and in vivo | Q35113722 | ||
| Erythropoietin both protects from and reverses experimental diabetic neuropathy | Q35554405 | ||
| Epoetin-associated pure red cell aplasia: past, present, and future considerations | Q37164738 | ||
| Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury | Q37250532 | ||
| Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin | Q38403090 | ||
| Derivatives of erythropoietin that are tissue protective but not erythropoietic | Q47213815 | ||
| Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects. | Q53943435 | ||
| Erythropoietin does not preserve motor neurons in a mouse model of familial ALS | Q58127127 | ||
| P433 | issue | 5-6 | |
| P921 | main subject | placebo | Q269829 |
| amyotrophic lateral sclerosis | Q206901 | ||
| erythropoietin | Q218706 | ||
| P304 | page(s) | 410-415 | |
| P577 | publication date | 2009-10-01 | |
| P1433 | published in | Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders | Q15759048 |
| P1476 | title | Erythropoietin in amyotrophic lateral sclerosis: a pilot, randomized, double-blind, placebo-controlled study of safety and tolerability. | |
| P478 | volume | 10 |
| Q26775401 | A comprehensive review of amyotrophic lateral sclerosis |
| Q38573829 | A retrospective review of the progress in amyotrophic lateral sclerosis drug discovery over the last decade and a look at the latest strategies |
| Q39008917 | A single blind randomized controlled clinical trial of mexiletine in amyotrophic lateral sclerosis: Efficacy and safety of sodium channel blocker phase II trial. |
| Q34554820 | ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment? |
| Q36422327 | Cervical spinal erythropoietin induces phrenic motor facilitation via extracellular signal-regulated protein kinase and Akt signaling |
| Q38260277 | Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? |
| Q42685032 | Current and emerging treatments for amyotrophic lateral sclerosis |
| Q64093623 | Erythropoietin and Friedreich Ataxia: Time for a Reappraisal? |
| Q92877211 | Erythropoietin as a Neuroprotective Molecule: An Overview of Its Therapeutic Potential in Neurodegenerative Diseases |
| Q82251921 | Erythropoietin concentration in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis |
| Q48833407 | Erythropoietin improves memory function with reducing endothelial dysfunction and amyloid-beta burden in Alzheimer's disease models |
| Q58451539 | Erythropoietin in Friedreich ataxia: No effect on frataxin in a randomized controlled trial |
| Q35891811 | Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study |
| Q92813735 | Glial Cells-The Strategic Targets in Amyotrophic Lateral Sclerosis Treatment |
| Q41837997 | Outcome measures in amyotrophic lateral sclerosis clinical trials |
| Q34504572 | Promises and pitfalls in erythopoietin-mediated tissue protection: are nonerythropoietic derivatives a way forward? |
| Q38432879 | Recombinant human erythropoietin in amyotrophic lateral sclerosis: a pilot study of safety and feasibility |
| Q42369773 | Shortcomings in the Current Amyotrophic Lateral Sclerosis Trials and Potential Solutions for Improvement |
| Q36214783 | Supplementation of a clinical trial by historical control data: is the prospect of dynamic borrowing an illusion? |
| Q24200285 | Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease |
| Q24241570 | Treatment for familial amyotrophic lateral sclerosis/motor neuron disease |
Search more.